PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth under 50% of AGEN's 19.89%. Michael Burry would be concerned about a severe competitive disadvantage.
8.25%
EBIT growth 50-75% of AGEN's 16.41%. Martin Whitman would suspect suboptimal resource allocation.
8.25%
Operating income growth at 50-75% of AGEN's 15.23%. Martin Whitman would doubt the firm’s ability to compete efficiently.
12.55%
Net income growth at 75-90% of AGEN's 15.29%. Bill Ackman would press for improvements to catch or surpass competitor performance.
15.52%
EPS growth at 50-75% of AGEN's 22.59%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
15.52%
Diluted EPS growth at 50-75% of AGEN's 21.29%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
3.21%
Share reduction more than 1.5x AGEN's 9.50%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.21%
Diluted share reduction more than 1.5x AGEN's 7.62%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.46%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
18.52%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
77.11%
5Y OCF/share CAGR above 1.5x AGEN's 19.06%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-27.06%
Negative 3Y OCF/share CAGR while AGEN stands at 0.37%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
72.83%
Net income/share CAGR above 1.5x AGEN's 31.80% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
70.62%
5Y net income/share CAGR above 1.5x AGEN's 42.91%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-36.68%
Negative 3Y CAGR while AGEN is 41.26%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
109.68%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-48.78%
Negative 5Y equity/share growth while AGEN is at 69.90%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-45.28%
Negative 3Y equity/share growth while AGEN is at 68.58%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AGEN invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-20.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.39%
We’re deleveraging while AGEN stands at 1.92%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.88%
R&D dropping or stable vs. AGEN's 37.16%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-40.17%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.